<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21664">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01860612</url>
  </required_header>
  <id_info>
    <org_study_id>AI-001</org_study_id>
    <nct_id>NCT01860612</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects</brief_title>
  <official_title>Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Research Consultants, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HumanOptics AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinical Research Consultants, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of an artificial iris
      prosthesis for the treatment of iris defects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in Symptoms</measure>
    <time_frame>SCR &amp; 6 Month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of vision will be assessed using the National Eye Institute Visual Functioning Questionnaire - 25.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant Satisfaction</measure>
    <time_frame>SCR &amp; 6 Month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participant satisfaction will be assessed using the Global Aesthetic Improvement Scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complications and Adverse Events</measure>
    <time_frame>SCR &amp; 6 Month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Complications and adverse events will be assessed through tabulation of adverse events, changes in vision, cell density, intraocular pressure, and slit lamp exam.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Full Aniridia</condition>
  <condition>Partial Aniridia</condition>
  <arm_group>
    <arm_group_label>PMA Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Compassionate Use Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study participants that do not meet the inclusion/exclusion criteria for the study may be enrolled in the compassionate use treatment arm. The artificial iris will be implanted in the eye with an iris defect. The fellow eye can be treated 1 month after the primary eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artificial Iris (CustomFlex)</intervention_name>
    <arm_group_label>PMA Cohort</arm_group_label>
    <arm_group_label>Compassionate Use Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 22 years of age or older

          2. Having a diagnosis of congenital or acquired full or partial iris defect in the study
             eye.

          3. Having symptoms of light sensitivity, photophobia, and/or glare in the study eye.

          4. Subjects should be pseudophakic, aphakic or require cataract extraction.

          5. Signed and received a copy of the signed written informed consent.

          6. Willingness and ability to comply with schedule for follow-up visits and
             postoperative evaluations.

        Exclusion Criteria:

          1. Uncontrolled ocular inflammation (e.g., uveitis).

          2. Preoperative intraocular pressure &gt; 21 mm Hg.

          3. Subjects with a current condition that, in the investigator's opinion, would
             interfere with the treatment.

          4. Subjects with any of the following conditions:

               1. Severe chronic uveitis

               2. Microphthalmus

               3. Untreated retinal detachment

               4. Untreated chronic glaucoma

               5. Rubella cataract

               6. Rubeosis of the iris

               7. Proliferative diabetic retinopathy

          5. Female subjects who are pregnant or lactating at the time of surgery.

          6. Subjects with a known sensitivity to required postoperative study medications (4th
             generation fluoroquinolone or steroid anti-inflammatory) if an alternative medication
             is not available.

          7. Subjects under legal guardianship or who, in the investigator's opinion, lack the
             mental capacity to provide written informed consent for study participation.

          8. Stargardt's retinopathy.

          9. Subjects with gastric ulcers or diabetes mellitus in whom high doses of postoperative
             steroids are required.

         10. Surgical difficulty of the planned surgery, which might increase the potential for
             complications.

         11. No useful vision or vision potential in the fellow eye.

         12. Clear crystalline lens.

         13. Implantation of a CustomFlex Artificial Iris prosthesis in the contralateral eye
             within the previous 4 weeks.

         14. In the investigator's opinion, the presence of a condition or finding in the
             contralateral eye that would make it unsafe to implant a CustomFlex Artificial Iris
             prosthesis in the study eye.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Barbara Fant</last_name>
    <phone>513-961-8200</phone>
    <email>bsfant@crc-regulatory.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Advanced Vision Care</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann McLean</last_name>
      <phone>310-229-1220</phone>
      <email>avcweb@aol.com</email>
    </contact>
    <investigator>
      <last_name>Samuel Masket, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manali Shah, M.D.</last_name>
      <email>shah@jsei.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Miller, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woolfson Eye Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodi Miller</last_name>
      <phone>770-804-1684</phone>
      <email>JMiller@woolfsoneye.com</email>
    </contact>
    <investigator>
      <last_name>R. Doyle Stulting, Ph.D. M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathey Kelley, O.D.</last_name>
      <phone>317-844-5530</phone>
      <email>kathykelley@pricevisiongroup.net</email>
    </contact>
    <investigator>
      <last_name>Francis Price, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leila Smaga</last_name>
      <email>Leila_Smaga@meei.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Roberto Pineda, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Eye Consultants</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Fallenstein</last_name>
      <phone>801-581-2352</phone>
      <email>lrfallenstein@mneye.com</email>
    </contact>
    <investigator>
      <last_name>David Hardten, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rosenthal Eye Surgery</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Butcher</last_name>
      <phone>516-504-9361</phone>
      <email>tech@eyesurgery.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth Rosenthal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Jost</last_name>
      <phone>513-984-5133</phone>
      <email>ajost@cincinnatieye.com</email>
    </contact>
    <investigator>
      <last_name>Michael Snyder, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Eye Associates</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Callina</last_name>
      <email>tlcallina@finemd.com</email>
    </contact>
    <investigator>
      <last_name>Richard Hoffman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wills Eye Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Spanelis</last_name>
      <phone>877-289-4557</phone>
      <email>Ispanelis@oppdoctors.com</email>
    </contact>
    <investigator>
      <last_name>Brandon Ayres, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alkek Eye Center/ Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stacy Malone</last_name>
      <phone>713-798-4125</phone>
      <email>slmalone@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Doug Koch, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Eye Institute of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Bachman</last_name>
      <phone>801-581-2352</phone>
      <email>kbachman@theeyeinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Robert Cionni, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 27, 2014</lastchanged_date>
  <firstreceived_date>May 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aniridia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
